CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Rosiglitazonedrug
Likely dose
Rosiglitazone 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00567593
NCT00567593Phase 4Completed
CompareCT.gov

Gene Regulation by Thiazolidinediones

James Lewis·interventional·Posted Dec 5, 2007·Updated Aug 1, 2016

In Brief

A Phase 4 clinical trial evaluating Rosiglitazone for Inflammatory Bowel Disease. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Disease
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2007
Enrollment StartOct 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.6 years ago

Interventions

Rosiglitazonedrug

8mg tablet once a day for 14 days